Amanta Healthcare Share Price Lists 5% Above Issue Price

Amanta Healthcare IPO opened for subscription on September 1, 2025, to September 3, 2025. 

It was a book-building issue of ₹126.00 crores. The issue is entirely a fresh issue of 1.00 crore shares of ₹126.00 crore. The Amanta Healthcare IPO price band was set at ₹126 per share. 

Amanta Healthcare’s IPO witnessed demand, being subscribed 82.60 times overall by September 3, 2025 (Day 3). The issue saw 54.96 times subscription in the retail category, 35.86 times in the QIB (Ex-Anchor) segment, and an impressive 209.40 times in the NII category.

The share allotment was finalised on Sep 4, 2025, and the shares were listed on BSE and NSE on Tuesday, Sep 9, 2025.

Amanta Healthcare Share Price

On the listing day, on the NSE, Amanta Healthcare share price (NSE: AMANTA) opened at ₹135.00, up from its issue price of ₹126.00. At 10:17 AM, the share price was trading at ₹133.40, up by 5.53% from its issue price and down by 1.19% from its opening price. As of the same time, the stock touched its day’s high at ₹139.00. The company’s market cap was ₹516.31 crore. 

On the BSE, at 10:18 AM, Amanta Healthcare share price was trading at ₹132.50, down by 1.12% from its opening price of ₹134.00 and 5.16% up from its issue price of ₹126.

About Amanta Healthcare Limited

Established in December 1994, Amanta Healthcare Limited is a pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of sterile liquid formulations, primarily parenteral products. These are packaged using advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies. The company also manufactures medical devices.

Also Read: Upcoming IPOs in September 2025!

Conclusion

Amanta Healthcare made a positive market debut, with shares trading above issue price on both NSE and BSE, reflecting investor interest.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.